Get started
Author

R. Stuart‐Harris

Observed names: R Stuart-Harris, R. C. STUART‐HARRIS, R. C. Stuart‐Harris, R. STUART-HARRIS, R. STUART‐HARRIS, R. Stuart-Harris, R. Stuart‐harris, R.C. Stuart-Harris, Rc Stuartharris, RobinC. Stuart-Harris
Observed institutions: Australian National University, Cedars-Sinai Medical Center, The University of Sydney, Guy's Hospital, St Bartholomew's Hospital, The Royal Melbourne Hospital, Royal Marsden NHS Foundation Trust, Mayo Clinic, The University of Melbourne, Ludwig Cancer Research, University of Wollongong, University of Cambridge, Royal Prince Alfred Hospital, Royal North Shore Hospital, Peter MacCallum Cancer Centre, Cancer Research UK, Wollongong Hospital, Nepean Hospital, Institut Jules Bordet, Sir Charles Gairdner Hospital, Canberra Hospital, Westmead Hospital, UNSW Sydney, Cancer Research UK Cambridge Center, Illawarra Shoalhaven Local Health District, Centre Léon Bérard, Ludwig Cancer Research, Royal Marsden Hospital, Ludwig Cancer Research, European Organisation for Research and Treatment of Cancer, Prince Charles Hospital, Ludwig Cancer Research, Act Health
OpenAlex ID: A5110097195
A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study.
1992 · P J Loehrer, L H Einhorn, et al. · Journal of Clinical Oncology · 981
Proliferation markers and survival in early breast cancer: A systematic review and meta-analysis of 85 studies in 32,825 patients
2008 · R. Stuart-Harris, C. Caldas, et al. · The Breast · 431
Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinoma
2018 · Olga Kondrashova, Monique Topp, et al. · Nature Communications · 298
PDF
Fear of cancer recurrence in young women with a history of early-stage breast cancer: a cross-sectional study of prevalence and association with health behaviours
2012 · B. Thewes, P. Butow, et al. · Supportive Care in Cancer · 213
Prognostic gene expression signature for high-grade serous ovarian cancer
2020 · J. Millstein, T. Budden, et al. · Annals of Oncology · 156
PDF
The importance of bleomycin in combination chemotherapy for good-prognosis germ cell carcinoma. Australasian Germ Cell Trial Group.
1993 · J A Levi, D Raghavan, et al. · Journal of Clinical Oncology · 133
High-dose alkylation therapy using ifosfamide infusion with mesna in the treatment of adult advanced soft-tissue sarcoma
1983 · RobinC. Stuart-Harris, PeterG. Harper, et al. · Cancer Chemotherapy and Pharmacology · 115
Carboplatin (CBDCA, JM-8) and VP-16-213 in previously untreated patients with small-cell lung cancer.
1987 · J F Bishop, D Raghavan, et al. · Journal of Clinical Oncology · 112
The pharmacokinetics of morphine and morphine glucuronide metabolites after subcutaneous bolus injection and subcutaneous infusion of morphine
2000 · R. Stuart‐harris, S. P. Joel, et al. · British Journal of Clinical Pharmacology · 95
PDF
Final results from the PERUSE study of first-line pertuzumab plus trastuzumab plus a taxane for HER2-positive locally recurrent or metastatic breast cancer, with a multivariable approach to guide prognostication
2021 · D. Miles, E. Ciruelos, et al. · Annals of Oncology · 94
PDF
Identifying priorities of psychosocial need in cancer patients
1990 · LP Liang, SM Dunn, et al. · British Journal of Cancer · 67
PDF
Clinical characteristics and outcomes of bilateral breast cancer in an Australian cohort
2010 · K.R. Beckmann, J. Buckingham, et al. · The Breast · 65
Low-dose Aminoglutethimide in Treatment of Advanced Breast Cancer
1984 · R Stuart-Harris, T Bozek, et al. · The Lancet · 62
High-dose ifosfamide by infusion with mesna in advanced soft tissue sarcoma
1983 · R. Stuart-Harris, P.G. Harper, et al. · Cancer Treatment Reviews · 57
Mitoxantrone: A phase II study in the treatment of patients with advanced breast carcinoma and other solid tumours
1982 · R.C. Stuart-Harris, I.E. Smith · Cancer Chemotherapy and Pharmacology · 57
Mitoxantrone: An active new agent in the treatment of advanced breast cancer
1984 · RobinC. Stuart-Harris, Thomas Bozek, et al. · Cancer Chemotherapy and Pharmacology · 53
A comparison of the endocrine effects of low dose aminoglutethimide with and without hydrocortisone in postmenopausal breast cancer patients
1985 · M Dowsett, A L Harris, et al. · British Journal of Cancer · 48
Refined cut-off for TP53 immunohistochemistry improves prediction of TP53 mutation status in ovarian mucinous tumors: implications for outcome analyses
2020 · Eun Young Kang, Dane Cheasley, et al. · Modern Pathology · 42
PDF
Extraskeletal Ewing's sarcoma: A clinical, morphological and ultrastructural analysis of five cases with a review of the literature
1986 · R. Stuart-Harris, E.J. Wills, et al. · European Journal of Cancer and Clinical Oncology · 42
Endocrine Effects of Low Dose Aminoglutethimide as an Aromatase Inhibitor in the Treatment of Breast Cancer
1985 · R. STUART‐HARRIS, M. DOWSETT, et al. · Clinical Endocrinology · 41
Tumour ploidy, response and survival in patients receiving endocrine therapy for advanced breast cancer
1985 · R Stuart-Harris, D W Hedley, et al. · British Journal of Cancer · 39
PDF
BRCA1 secondary splice-site mutations drive exon-skipping and PARP inhibitor resistance
2024 · Ksenija Nesic, John J. Krais, et al. · Molecular Cancer · 36
PDF
Chemotherapy of Endodermal Sinus Tumour (Yolk Sac Tumour) of the Ovary: Preliminary Communication
1982 · E Wiltshaw, R Stuart-Harris, et al. · Journal of the Royal Society of Medicine · 36
PDF
Phase II study of mitoxantrone in patients with mesothelioma: a National Cancer Institute of Canada Clinical Trials Group Study.
1986 · E A Eisenhauer, W K Evans, et al. · PubMed · 35
Role of aminoglutethimide in male breast cancer
1987 · A L Harris, M Dowsett, et al. · British Journal of Cancer · 33
PDF
Works count: 70
Citation count: 3,744
H-index: 28
I10-index: 42
Year
Topic
Type